A novel silk-based vocal fold augmentation material: 6-month evaluation in a canine model.


Journal

The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378

Informations de publication

Date de publication:
08 2019
Historique:
received: 21 03 2018
revised: 03 08 2018
accepted: 17 09 2018
pubmed: 28 12 2018
medline: 21 8 2019
entrez: 28 12 2018
Statut: ppublish

Résumé

Ideal long-term vocal fold augmentation materials should be biocompatible, easily administered, allow tissue integration for long-term effect, and remain at the site of injection. A novel silk protein particle suspended in hyaluronic acid (Silk-HA) has been developed specifically for vocal fold augmentation to address this unmet need. This article presents the 6-month, preclinical findings of a canine vocal fold injection trial for Silk-HA. Twelve beagle dogs were injected transorally in the lateral/deep aspect of their right thyroarytenoid muscles with 0.3 cc of Silk-HA or calcium hydroxylapatite in carboxymethyl cellulose (CaHA-CMC). The Silk-HA particle injectable was delivered via a custom catheter, whereas CaHA-CMC was delivered through a commercially available malleable needle. The six dogs from each material group were sacrificed 6 months from the injection date for the evaluation of implant longevity, immune response, and material migration. Silk-HA provides immediate medialization of the right vocal fold, lasting for a minimum of 6 months in a canine model. Silk-HA and CaHA-CMC both demonstrate similar inflammatory responses. The Silk-HA was shown to remain without migration at the site of injection in all six canine subjects, whereas CaHA-CMC demonstrated migration in four of the six canines. In two canines implanted with CaHA-CMC, material was discovered to migrate to the retropharyngeal lymph nodes. In a canine subject model, the Silk-HA material compares favorably in terms of longevity and immune response to CaHA-CMC. The lack of migration of the Silk-HA material demonstrates a promising potential for vocal fold injection in the clinic. NA Laryngoscope, 129:1856-1862, 2019.

Identifiants

pubmed: 30588626
doi: 10.1002/lary.27618
doi:

Substances chimiques

Biocompatible Materials 0
Silk 0
Hyaluronic Acid 9004-61-9
Durapatite 91D9GV0Z28
Carboxymethylcellulose Sodium K679OBS311

Types de publication

Journal Article

Langues

eng

Pagination

1856-1862

Informations de copyright

© 2018 The American Laryngological, Rhinological and Otological Society, Inc.

Auteurs

Christopher P Gulka (CP)

Sofregen Medical, Inc., Medford.

Joseph E Brown (JE)

Sofregen Medical, Inc., Medford.

Jodie E M Giordano (JEM)

Sofregen Medical, Inc., Medford.

Jennifer E Hickey (JE)

Sofregen Medical, Inc., Medford.

Maria P Montero (MP)

Sofregen Medical, Inc., Medford.

Anh Hoang (A)

Sofregen Medical, Inc., Medford.

Thomas L Carroll (TL)

Department of Otolaryngology, Brigham and Women's Hospital, Boston, Massachusetts, U.S.A.

Articles similaires

Humans Meals Time Factors Female Adult

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

Classifications MeSH